Jan 29, 2026
Most ViewedGlp1 drug lawsuits
The are a fast‑growing mass‑tort movement alleging that widely prescribed glucagon‑like peptide‑1 receptor agonists — including , and — caused serious harms such as , intestinal blockages and vision l...
GLP-1+ Medicines Development
The development of GLP-1+ and multi-agonist medicines, including Novo Nordisk's CagriSema and retatrutide.
Fact-Checks
3 resultsFeb 6, 2026
Trumps RX program reducing cost of Zepbound
is being promoted by as delivering steep cuts to the cash price of weight‑loss drug —dropping advertised monthly list prices from roughly $1,086 to averages near $346 and lows of $299 for self‑pay cus...
Jan 14, 2026
Which oral GLP‑1 and multi‑agonist drugs are nearest FDA approval and how might their costs differ from injectables?
Two oral GLP‑1 pills are effectively already at the finish line: Novo Nordisk’s oral semaglutide (Wegovy pill) received FDA approval in late 2025 with a U.S. launch planned for early January 2026, and...